Correspondence sent from Tom Jefferson to the European Medicines Agency on 3 December 2012.
All rapid responses
Tom Jefferson responds to the letter from the EMA (below). He believes it shows that they are not comfortable taking a strong position with respect to Tamiflu's effect on risk of complications, though it does not appear that they have carried out their own analysis to confirm the fact, and are accepting Roche's analysis at face value. This reply requests more documentation regarding this from the EMA.
They do however state unambiguously that Roche's clinical trial does not show that Tamiflu reduces transmission as has been claimed in the past.
Competing interests: No competing interests